With 0.23 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.28 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.7100 whereas the lowest price it dropped to was $0.6510. The 52-week range on MTNB shows that it touched its highest point at $1.16 and its lowest point at $0.49 during that stretch. It currently has a 1-year price target of $2.75. Beta for the stock currently stands at 1.96.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MTNB was up-trending over the past week, with a rise of 1.47%, but this was down by -13.95% over a month. Three-month performance dropped to -6.88% while six-month performance fell -1.40%. The stock lost -34.29% in the past year, while it has lost -31.68% so far this year. A look at the trailing 12-month EPS for MTNB yields -0.11 with Next year EPS estimates of -0.10. For the next quarter, that number is -0.02. This implies an EPS growth rate of 4.50% for this year and 0.00% for next year.
Float and Shares Shorts:
At present, 216.87 million MTNB shares are outstanding with a float of 208.61 million shares on hand for trading. On Oct 13, 2022, short shares totaled 1.61 million, which was 0.74% higher than short shares on Sep 14, 2022. In addition to Mr. Jerome D. Jabbour J.D. as the firm’s Co-Founder, CEO, Pres & Director, Dr. Theresa Matkovits Ph.D. serves as its Chief Devel. Officer.
Through their ownership of 12.70% of MTNB’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 6.91% of MTNB, in contrast to 6.08% held by mutual funds. Shares owned by individuals account for 11.19%. As the largest shareholder in MTNB with 3.86% of the stake, The Vanguard Group, Inc. holds 8,363,232 shares worth 8,363,232. A second-largest stockholder of MTNB, BlackRock Fund Advisors, holds 4,272,673 shares, controlling over 1.97% of the firm’s shares. Sargent Investment Group LLC is the third largest shareholder in MTNB, holding 4,207,337 shares or 1.94% stake. With a 2.64% stake in MTNB, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 5,720,245 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.09% of MTNB stock, is the second-largest Mutual Fund holder. It holds 2,357,696 shares valued at 1.84 million. iShares Biotechnology ETF holds 0.79% of the stake in MTNB, owning 1,715,564 shares worth 1.34 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MTNB since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With MTNB analysts setting a high price target of $3.00 and a low target of $2.00, the average target price over the next 12 months is $2.75. Based on these targets, MTNB could surge 334.78% to reach the target high and rise by 189.86% to reach the target low. Reaching the average price target will result in a growth of 298.55% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. MTNB will report FY 2022 earnings on 04/04/2023. Analysts have provided yearly estimates in a range of -$0.08 being high and -$0.11 being low. For MTNB, this leads to a yearly average estimate of -$0.10. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Matinas BioPharma Holdings Inc. surprised analysts by -$0.00 when it reported -$0.03 EPS against a consensus estimate of -$0.03. The surprise factor in the prior quarter was $0.00. Based on analyst estimates, the high estimate for the next quarter is $0.01 and the low estimate is -$0.03. The average estimate for the next quarter is thus -$0.02.
Summary of Insider Activity:
Insiders traded MTNB stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 2 while that of sell transactions has risen to 1 over the past year. The total number of shares bought during that period was 1,365,981 while 1,358,122 shares were sold.